首页 > 最新文献

Journal of Thoracic Oncology最新文献

英文 中文
Safety, efficacy and biomarker analysis of deulorlatinib (TGRX-326) in ALK-positive non-small-cell lung cancer: a multicentre, open-label, phase 1/1b trial. ALK阳性非小细胞肺癌患者服用deulorlatinib(TGRX-326)的安全性、疗效和生物标志物分析:一项多中心、开放标签、1/1b期试验。
IF 21 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-15 DOI: 10.1016/j.jtho.2024.11.010
Shen Zhao, Huaqiang Zhou, Nong Yang, Zhehai Wang, Wenjian Jin, Yuxiang Ma, Jinhui Xue, Xingya Li, Yunpeng Liu, Rui Meng, Jianying Zhou, Ying Cheng, Yongsheng Wang, Zhuang Yu, Yu Cao, Yuanyuan Zhao, Yan Huang, Wenfeng Fang, Yang Zhang, Shaodong Hong, Bo Wu, Yanxia Shi, Jingrong Cao, Mingyan Xu, Xiaoni Zhang, Longyu Hu, Bo Peng, Yunpeng Yang, Li Zhang, Hongyun Zhao

Introduction: Patients with ALK-positive NSCLC developing resistance to second-generation inhibitors have limited treatment options. Deulorlatinib is a highly brain-penetrant, new-generation ALK/ROS1 inhibitor. We evaluated the safety, efficacy and pharmacokinetics of deulorlatinib in ALK-positive NSCLC.

Methods: This 3-part (dose-escalation/dose-expansion/cohort-expansion), open-label, phase 1/1b trial was conducted at 22 sites in China (ClinicalTrials.gov, NCT05441956). Eligible patients had advanced ALK/ROS1-positive NSCLC. Patients enrolled into dose-escalation/dose-expansion parts were previously treated with ≥1 second-generation ALK inhibitors (ALK-positive) or crizotinib (ROS1-positive); received deulorlatinib 5-125mg once daily. Patients enrolled into cohort-expansion parts were either crizotinib-treated, second-generation TKI-treated or TKI-naïve; received deulorlatinib at recommended phase 2 dose (RP2D). Primary outcomes were safety and tolerability. Here, we report safety analysis in all patients and efficacy analysis in ALK-positive patients.

Results: Between April 2021 and March 2023, 198 patients were enrolled (ALK-positive=171, ROS1-positive=27). Most common treatment-related adverse events (TRAEs) were hypercholesterolemia (79.3%), hypertriglyceridemia (77.3%) and weight gain (53.0%). 40.4% of patients had grade≥3 TRAEs. TRAE-associated dose interruptions, reduction and discontinuation occurred in 11.1%, 3.0% and 1.5% of patients, respectively. The RP2D was set at 60mg once daily. A total of 144 ALK-positive patients were treated at RP2D. For crizotinib-treated (n=14), second-generation TKI-treated (n=97) and TKI-naïve (n=33) patients, ORR to deulorlatinib at RP2D was 71.4%, 38.1%, and 87.9%, respectively. Intracranial ORR was 50%, 70.4%, and 75%. Median duration of response was 18.0 months for second-generation TKI-treated patients, and not reached for crizotinib-treated and TKI-naïve patients. Biomarker analyses identified undetectable ALK alterations at baseline and ALK ctDNA clearance at week 6 as potential predictive biomarkers.

Conclusions: Deulorlatinib showed desirable tolerability and efficacy in ALK-positive NSCLC, demonstrating the potential to become a new treatment option in this population.

简介:对第二代抑制剂产生耐药性的ALK阳性NSCLC患者的治疗选择非常有限。德洛拉替尼是一种高度脑穿透性的新一代ALK/ROS1抑制剂。我们评估了德欧拉替尼在ALK阳性NSCLC中的安全性、有效性和药代动力学:这项由三部分组成(剂量递增/剂量扩增/皮质扩增)、开放标签、1/1b 期试验在中国 22 个地点进行(ClinicalTrials.gov,NCT05441956)。符合条件的患者均为 ALK/ROS1 阳性的晚期 NSCLC。入组剂量递增/剂量扩增部分的患者既往接受过≥1种第二代ALK抑制剂(ALK阳性)或克唑替尼(ROS1阳性)治疗;接受每日1次、每次5-125毫克的deulorlatinib治疗。加入队列扩展部分的患者要么接受过克唑替尼治疗,要么接受过第二代TKI治疗,要么TKI治疗无效;接受推荐的2期剂量(RP2D)的deulorlatinib治疗。主要结果是安全性和耐受性。在此,我们报告所有患者的安全性分析和ALK阳性患者的疗效分析:2021年4月至2023年3月期间,共有198例患者入组(ALK阳性=171例,ROS1阳性=27例)。最常见的治疗相关不良事件(TRAEs)为高胆固醇血症(79.3%)、高甘油三酯血症(77.3%)和体重增加(53.0%)。40.4%的患者出现≥3级TRAE。分别有11.1%、3.0%和1.5%的患者出现与TRAE相关的剂量中断、减少和中止。RP2D设定为60毫克,每日一次。共有144名ALK阳性患者接受了RP2D治疗。在克唑替尼治疗(14例)、第二代TKI治疗(97例)和TKI治疗无效(33例)的患者中,RP2D时去氯拉替尼的ORR分别为71.4%、38.1%和87.9%。颅内ORR分别为50%、70.4%和75%。第二代TKI治疗患者的中位应答持续时间为18.0个月,克唑替尼治疗和TKI治疗无效患者的中位应答持续时间未达到18.0个月。生物标志物分析发现,基线检测不到的ALK改变和第6周的ALK ctDNA清除率是潜在的预测性生物标志物:德洛拉替尼在ALK阳性NSCLC患者中显示出理想的耐受性和疗效,表明它有可能成为该人群的一种新的治疗选择。
{"title":"Safety, efficacy and biomarker analysis of deulorlatinib (TGRX-326) in ALK-positive non-small-cell lung cancer: a multicentre, open-label, phase 1/1b trial.","authors":"Shen Zhao, Huaqiang Zhou, Nong Yang, Zhehai Wang, Wenjian Jin, Yuxiang Ma, Jinhui Xue, Xingya Li, Yunpeng Liu, Rui Meng, Jianying Zhou, Ying Cheng, Yongsheng Wang, Zhuang Yu, Yu Cao, Yuanyuan Zhao, Yan Huang, Wenfeng Fang, Yang Zhang, Shaodong Hong, Bo Wu, Yanxia Shi, Jingrong Cao, Mingyan Xu, Xiaoni Zhang, Longyu Hu, Bo Peng, Yunpeng Yang, Li Zhang, Hongyun Zhao","doi":"10.1016/j.jtho.2024.11.010","DOIUrl":"https://doi.org/10.1016/j.jtho.2024.11.010","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with ALK-positive NSCLC developing resistance to second-generation inhibitors have limited treatment options. Deulorlatinib is a highly brain-penetrant, new-generation ALK/ROS1 inhibitor. We evaluated the safety, efficacy and pharmacokinetics of deulorlatinib in ALK-positive NSCLC.</p><p><strong>Methods: </strong>This 3-part (dose-escalation/dose-expansion/cohort-expansion), open-label, phase 1/1b trial was conducted at 22 sites in China (ClinicalTrials.gov, NCT05441956). Eligible patients had advanced ALK/ROS1-positive NSCLC. Patients enrolled into dose-escalation/dose-expansion parts were previously treated with ≥1 second-generation ALK inhibitors (ALK-positive) or crizotinib (ROS1-positive); received deulorlatinib 5-125mg once daily. Patients enrolled into cohort-expansion parts were either crizotinib-treated, second-generation TKI-treated or TKI-naïve; received deulorlatinib at recommended phase 2 dose (RP2D). Primary outcomes were safety and tolerability. Here, we report safety analysis in all patients and efficacy analysis in ALK-positive patients.</p><p><strong>Results: </strong>Between April 2021 and March 2023, 198 patients were enrolled (ALK-positive=171, ROS1-positive=27). Most common treatment-related adverse events (TRAEs) were hypercholesterolemia (79.3%), hypertriglyceridemia (77.3%) and weight gain (53.0%). 40.4% of patients had grade≥3 TRAEs. TRAE-associated dose interruptions, reduction and discontinuation occurred in 11.1%, 3.0% and 1.5% of patients, respectively. The RP2D was set at 60mg once daily. A total of 144 ALK-positive patients were treated at RP2D. For crizotinib-treated (n=14), second-generation TKI-treated (n=97) and TKI-naïve (n=33) patients, ORR to deulorlatinib at RP2D was 71.4%, 38.1%, and 87.9%, respectively. Intracranial ORR was 50%, 70.4%, and 75%. Median duration of response was 18.0 months for second-generation TKI-treated patients, and not reached for crizotinib-treated and TKI-naïve patients. Biomarker analyses identified undetectable ALK alterations at baseline and ALK ctDNA clearance at week 6 as potential predictive biomarkers.</p><p><strong>Conclusions: </strong>Deulorlatinib showed desirable tolerability and efficacy in ALK-positive NSCLC, demonstrating the potential to become a new treatment option in this population.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PCI for Patients with Small Cell Lung Cancer: A New Perspective in the Immunotherapy Era. 小细胞肺癌患者的 PCI 治疗:免疫疗法时代的新视角。
IF 21 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-15 DOI: 10.1016/j.jtho.2024.11.011
Antonin Levy, Chad G Rusthoven, Paul D Brown, Cécile Le Péchoux, Corinne Faivre-Finn

Prophylactic cranial irradiation (PCI) has long been used for small-cell lung cancer (SCLC) to reduce the risk of brain metastases and potentially improve overall survival. However, recent immunotherapy trials have provided limited data on its impact, as few patients were treated with PCI. The ADRIATIC trial demonstrated improved outcomes with consolidation immunotherapy in limited-stage SCLC, and PCI was a stratification factor. Notably, patients receiving PCI in both arms had better outcomes compared to those who did not. Ongoing studies, such as EORTC-1901 PRIMALung (NCT04790253) and SWOG 1827-MAVERICK (NCT04155034), are further investigating PCI's role in the era of immunotherapy, highlighting its potential importance in evolving treatment strategies.

长期以来,预防性颅脑照射(PCI)一直被用于小细胞肺癌(SCLC)的治疗,以降低脑转移的风险,并有可能提高总生存率。然而,最近的免疫疗法试验对其影响提供的数据有限,因为只有少数患者接受了PCI治疗。ADRIATIC 试验表明,在有限分期的 SCLC 中,巩固免疫疗法可改善疗效,而 PCI 是一个分层因素。值得注意的是,两组接受 PCI 治疗的患者与未接受 PCI 治疗的患者相比,疗效更好。EORTC-1901 PRIMALung(NCT04790253)和SWOG 1827-MAVERICK(NCT04155034)等正在进行的研究正在进一步研究PCI在免疫疗法时代的作用,突出了PCI在不断发展的治疗策略中的潜在重要性。
{"title":"PCI for Patients with Small Cell Lung Cancer: A New Perspective in the Immunotherapy Era.","authors":"Antonin Levy, Chad G Rusthoven, Paul D Brown, Cécile Le Péchoux, Corinne Faivre-Finn","doi":"10.1016/j.jtho.2024.11.011","DOIUrl":"https://doi.org/10.1016/j.jtho.2024.11.011","url":null,"abstract":"<p><p>Prophylactic cranial irradiation (PCI) has long been used for small-cell lung cancer (SCLC) to reduce the risk of brain metastases and potentially improve overall survival. However, recent immunotherapy trials have provided limited data on its impact, as few patients were treated with PCI. The ADRIATIC trial demonstrated improved outcomes with consolidation immunotherapy in limited-stage SCLC, and PCI was a stratification factor. Notably, patients receiving PCI in both arms had better outcomes compared to those who did not. Ongoing studies, such as EORTC-1901 PRIMALung (NCT04790253) and SWOG 1827-MAVERICK (NCT04155034), are further investigating PCI's role in the era of immunotherapy, highlighting its potential importance in evolving treatment strategies.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predicted effect of incidental pulmonary nodule findings on Non-Small Cell Lung Cancer mortality. 偶然发现肺结节对非小细胞肺癌死亡率的预测影响。
IF 21 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-12 DOI: 10.1016/j.jtho.2024.11.009
S Tuminello, R Flores, M Untalan, T Ivic-Pavlicic, C I Henschke, R Yip, D F Yankelevitz, E Taioli

Introduction: Despite the reduction in mortality shown by Low dose computer tomography (LDCT) lung cancer screening, the uptake is still low. Patients undergo chest imaging for several other medical reasons, and this is a unique opportunity to detect lung nodules.

Methods: In a cohort of NSCLC patients from the Surveillance, Epidemiology and End Results (SEER)-Medicare linked data, tumor size at previous imaging was calculated as: VDT = [(T2-T1)·ln2]/ln(V2/V1), solving for diameter of V1. V1 and V2 are tumor volume at times T1 (previous imaging) and T2 (diagnostic procedure) according to three different growth models. 10-year lung cancer-specific mortality was calculated as: lung cancer survival rate = (-0.0098 × maximum tumor diameter) + 1.

Results: 1,007 patients who had a chest imaging performed up to one year prior to lung cancer diagnosis. The median size of the tumor at diagnosis was 25 mm, the predicted median tumor size at previous imaging was 12.16 mm, 17.3 mm, and 20.42 mm under the fast, medium and slow growth model. Under the fast growth model, a detection of the nodule at previous imaging would have yield a decrease in mortality of 7.79%; the corresponding values for the medium growth model is 4.5%, for the slow growth model 2.45%.

Conclusions: Identifying malignant lung nodules in imaging performed for other clinical reasons can help decreasing the burden of NSCLC, especially for non-LDCT eligible patients and the medically vulnerable. We show here that clinical benefits, especially among patients with aggressive disease, can be considerable.

简介尽管低剂量计算机断层扫描(LDCT)肺癌筛查降低了死亡率,但接受率仍然很低。患者接受胸部成像检查还有其他一些医疗原因,而这正是检测肺结节的独特机会:在监测、流行病学和终末结果(SEER)--医疗保险链接数据中的 NSCLC 患者队列中,上次成像时肿瘤大小的计算方法为VDT = [(T2-T1)-ln2]/ln(V2/V1),求解 V1 的直径。根据三种不同的生长模型,V1 和 V2 分别为 T1(上次成像)和 T2(诊断过程)时的肿瘤体积。10 年肺癌特异性死亡率的计算公式为:肺癌生存率 = (-0.0098 × 最大肿瘤直径) + 1.结果:1007 名患者在确诊肺癌前一年进行了胸部成像检查。确诊时肿瘤的中位尺寸为 25 毫米,在快速、中速和慢速生长模型下,预测的上次成像时肿瘤的中位尺寸分别为 12.16 毫米、17.3 毫米和 20.42 毫米。在快速生长模型下,如果在之前的成像中发现结节,死亡率将降低 7.79%;中速生长模型的相应数值为 4.5%,慢速生长模型为 2.45%:在因其他临床原因而进行的成像中识别恶性肺结节有助于减轻 NSCLC 的负担,尤其是对于不符合LDCT 条件的患者和医学上的弱势群体。我们在此表明,临床获益,尤其是侵袭性疾病患者的获益,是相当可观的。
{"title":"Predicted effect of incidental pulmonary nodule findings on Non-Small Cell Lung Cancer mortality.","authors":"S Tuminello, R Flores, M Untalan, T Ivic-Pavlicic, C I Henschke, R Yip, D F Yankelevitz, E Taioli","doi":"10.1016/j.jtho.2024.11.009","DOIUrl":"10.1016/j.jtho.2024.11.009","url":null,"abstract":"<p><strong>Introduction: </strong>Despite the reduction in mortality shown by Low dose computer tomography (LDCT) lung cancer screening, the uptake is still low. Patients undergo chest imaging for several other medical reasons, and this is a unique opportunity to detect lung nodules.</p><p><strong>Methods: </strong>In a cohort of NSCLC patients from the Surveillance, Epidemiology and End Results (SEER)-Medicare linked data, tumor size at previous imaging was calculated as: VDT = [(T<sub>2</sub>-T<sub>1</sub>)·ln2]/ln(V<sub>2</sub>/V<sub>1</sub>), solving for diameter of V<sub>1</sub>. V<sub>1</sub> and V<sub>2</sub> are tumor volume at times T<sub>1</sub> (previous imaging) and T<sub>2</sub> (diagnostic procedure) according to three different growth models. 10-year lung cancer-specific mortality was calculated as: lung cancer survival rate = (-0.0098 × maximum tumor diameter) + 1.</p><p><strong>Results: </strong>1,007 patients who had a chest imaging performed up to one year prior to lung cancer diagnosis. The median size of the tumor at diagnosis was 25 mm, the predicted median tumor size at previous imaging was 12.16 mm, 17.3 mm, and 20.42 mm under the fast, medium and slow growth model. Under the fast growth model, a detection of the nodule at previous imaging would have yield a decrease in mortality of 7.79%; the corresponding values for the medium growth model is 4.5%, for the slow growth model 2.45%.</p><p><strong>Conclusions: </strong>Identifying malignant lung nodules in imaging performed for other clinical reasons can help decreasing the burden of NSCLC, especially for non-LDCT eligible patients and the medically vulnerable. We show here that clinical benefits, especially among patients with aggressive disease, can be considerable.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DSTYK Inhibition Sensitizes Non-Small Cell Lung Cancer To Taxane-Based Chemotherapy. 抑制 DSTYK 可使非小细胞肺癌对基于紫杉烷的化疗敏感
IF 21 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-11 DOI: 10.1016/j.jtho.2024.11.003
Mirari Echepare, Beñat Picabea, Andrea Arricibita, Álvaro Teijeira, Andrea Pasquier, Carolina Zandueta, Nerea Otegui, Enrique Santamaría, Joaquín Fernández-Irigoyen, Octavio Romero, Montse Sanchez-Cespedes, Fernando Lecanda, Javier Hernández, Enriqueta Felip, Alberto Cruz-Bermúdez, Mariano Provencio, Marco Gentili, Federica Facchinetti, Luca Roz, Luis M Montuenga, Karmele Valencia

Chemotherapy continues to be the standard treatment for patients non-eligible to targeted or immune-based therapies; however, treatment resistance remains a major clinical challenge. We previously found that expression levels of DSTYK, a poorly explored dual serine/threonine and tyrosine kinase frequently amplified in cancer, identifies lung cancer patients exhibiting poor response to immune checkpoint inhibitors and showed that its inhibition sensitizes to immunotherapy. Seeking to explore the potential of DSTYK targeting in additional indications, we investigated the functional relevance and actionability of DSTYK in lung cancer chemoresistance. We show that DSTYK depletion specifically sensitizes lung cancer cells to taxane-based chemotherapy, particularly in combination with carboplatin. Mechanistically, DSTYK ablation remodels the cytoskeleton and impairs distant invasion and metastatic outgrowth in vivo. DSTYK downregulation sensitizes both primary and metastatic lung tumors to chemoimmunotherapy treatment leading to tumor regression in mouse models. Consistently, clinical data of early - in the neoadjuvant and adjuvant settings- and advanced lung cancer patients show a strong correlation between DSTYK amplification and taxane resistance, underscoring the clinical significance of our findings to inform treatment decision-making. Collectively, our data indicates that DSTYK amplification may be a predictor of resistance to taxane-based treatments and represents an actionable target for these patients.

化疗仍然是不符合靶向或免疫疗法条件的患者的标准治疗方法;然而,治疗耐药性仍然是一项重大的临床挑战。我们以前曾发现,DSTYK(一种在癌症中经常扩增的丝氨酸/苏氨酸和酪氨酸双重激酶)的表达水平很低,它能识别对免疫检查点抑制剂反应不佳的肺癌患者,并表明抑制它能使免疫疗法敏感。为了探索 DSTYK 靶向在其他适应症中的潜力,我们研究了 DSTYK 在肺癌化疗耐药性中的功能相关性和可操作性。我们的研究表明,DSTYK 基因耗竭可使肺癌细胞对以紫杉类药物为基础的化疗产生特异性敏感性,尤其是在与卡铂联合化疗时。从机理上讲,DSTYK消减可重塑细胞骨架,并损害体内的远处侵袭和转移生长。下调 DSTYK 可使原发性和转移性肺肿瘤对化疗免疫疗法敏感,从而导致小鼠模型中肿瘤的消退。同样,早期肺癌(新辅助治疗和辅助治疗)和晚期肺癌患者的临床数据显示,DSTYK 扩增与紫杉类药物耐药性之间存在很强的相关性,这凸显了我们的研究结果对治疗决策的临床意义。总之,我们的数据表明,DSTYK扩增可能是对以紫杉类药物为基础的治疗产生耐药性的一个预测因子,也是这些患者的一个可行靶点。
{"title":"DSTYK Inhibition Sensitizes Non-Small Cell Lung Cancer To Taxane-Based Chemotherapy.","authors":"Mirari Echepare, Beñat Picabea, Andrea Arricibita, Álvaro Teijeira, Andrea Pasquier, Carolina Zandueta, Nerea Otegui, Enrique Santamaría, Joaquín Fernández-Irigoyen, Octavio Romero, Montse Sanchez-Cespedes, Fernando Lecanda, Javier Hernández, Enriqueta Felip, Alberto Cruz-Bermúdez, Mariano Provencio, Marco Gentili, Federica Facchinetti, Luca Roz, Luis M Montuenga, Karmele Valencia","doi":"10.1016/j.jtho.2024.11.003","DOIUrl":"https://doi.org/10.1016/j.jtho.2024.11.003","url":null,"abstract":"<p><p>Chemotherapy continues to be the standard treatment for patients non-eligible to targeted or immune-based therapies; however, treatment resistance remains a major clinical challenge. We previously found that expression levels of DSTYK, a poorly explored dual serine/threonine and tyrosine kinase frequently amplified in cancer, identifies lung cancer patients exhibiting poor response to immune checkpoint inhibitors and showed that its inhibition sensitizes to immunotherapy. Seeking to explore the potential of DSTYK targeting in additional indications, we investigated the functional relevance and actionability of DSTYK in lung cancer chemoresistance. We show that DSTYK depletion specifically sensitizes lung cancer cells to taxane-based chemotherapy, particularly in combination with carboplatin. Mechanistically, DSTYK ablation remodels the cytoskeleton and impairs distant invasion and metastatic outgrowth in vivo. DSTYK downregulation sensitizes both primary and metastatic lung tumors to chemoimmunotherapy treatment leading to tumor regression in mouse models. Consistently, clinical data of early - in the neoadjuvant and adjuvant settings- and advanced lung cancer patients show a strong correlation between DSTYK amplification and taxane resistance, underscoring the clinical significance of our findings to inform treatment decision-making. Collectively, our data indicates that DSTYK amplification may be a predictor of resistance to taxane-based treatments and represents an actionable target for these patients.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression ≥25%: Results from the Randomized Phase 3 PEARL Study. Durvalumab与化疗作为肿瘤PD-L1表达≥25%的转移性NSCLC的一线治疗:随机 3 期 PEARL 研究结果。
IF 21 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-07 DOI: 10.1016/j.jtho.2024.10.024
Shun Lu, Lin Wu, Qiming Wang, Ziping Wang, Dongqing Lv, Rui Ma, Bo Zhu, Ngoc van Tran, Liyan Jiang, Kejun Nan, Konstantin Laktionov, Stephen Clarke, Minghao Song, Helen Mann, Yinglei Liu, Xiaojin Shi, Yi-Long Wu

Introduction: PEARL (NCT03003962) is an open-label, phase 3 study comparing first-line durvalumab monotherapy with chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC [EGFR/ALK wild type]) with PD-L1 tumor cell (TC) membrane expression status ≥25%. We report the final analysis of PEARL.

Methods: Adults (N=669) with previously untreated Stage IV mNSCLC were randomized (1:1) to durvalumab 20mg/kg every 4 weeks or chemotherapy every 3 weeks for 4 to 6 cycles. Dual primary endpoints were overall survival (OS) in the PD-L1 TC ≥25% and the PD-L1 TC ≥25% low risk of early mortality (LREM) populations.

Results: Durvalumab was associated with a numerical reduction in the risk of death versus chemotherapy in the PD-L1 TC ≥25% population (OS hazard ratio [HR] 0.84, 95% confidence interval [CI] 0.71, 0.99, p = 0.037; median OS 14.6 months [95% CI: 12.2, 16.9] versus 12.8 months [95% CI: 10.1, 14.7], respectively). In the PD-L1 TC ≥25% LREM population the OS HR for durvalumab versus chemotherapy was 0.96 (95% CI: 0.79, 1.15, p = 0.628); median OS 14.6 months (95% CI: 12.6, 17.2) versus 15.0 months (95% CI: 13.1, 16.8), respectively. In the safety population, the incidence of grade 3/4 treatment-related adverse events was 15.5% (durvalumab) and 45.9% (chemotherapy).

Conclusions: Durvalumab did not statistically significantly improve OS versus chemotherapy as first-line treatment in patients with mNSCLC and PD-L1 TC ≥25%. The numerical improvement in OS was consistent with previous studies of first-line immune checkpoint inhibitor monotherapy in patients with mNSCLC.

研究简介PEARL(NCT03003962)是一项开放标签的3期研究,比较了PD-L1肿瘤细胞(TC)膜表达状态≥25%的转移性非小细胞肺癌(mNSCLC [表皮生长因子受体/ALK野生型])患者一线使用durvalumab单药与化疗的效果。我们报告了 PEARL 的最终分析结果:既往未经治疗的 IV 期 mNSCLC 成人患者(N=669)被随机(1:1)分配到每 4 周一次的 durvalumab 20mg/kg 或每 3 周一次的化疗,共 4 到 6 个周期。双重主要终点是PD-L1 TC≥25%人群和PD-L1 TC≥25%低早期死亡风险(LREM)人群的总生存期(OS):在PD-L1 TC≥25%的人群中,Durvalumab与化疗相比可降低死亡风险(OS危险比[HR]0.84,95%置信区间[CI]0.71,0.99,P = 0.037;中位OS分别为14.6个月[95% CI:12.2,16.9]和12.8个月[95% CI:10.1,14.7])。在PD-L1 TC≥25% LREM人群中,durvalumab与化疗相比的OS HR为0.96(95% CI:0.79,1.15,p = 0.628);中位OS分别为14.6个月(95% CI:12.6,17.2)与15.0个月(95% CI:13.1,16.8)。在安全性研究人群中,3/4级治疗相关不良事件的发生率为15.5%(杜伐单抗)和45.9%(化疗):结论:对于PD-L1 TC≥25%的mNSCLC一线治疗患者,与化疗相比,Durvalumab在统计学上并未显著改善患者的OS。OS的数值改善与之前对mNSCLC患者进行的一线免疫检查点抑制剂单药治疗研究结果一致。
{"title":"Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression ≥25%: Results from the Randomized Phase 3 PEARL Study.","authors":"Shun Lu, Lin Wu, Qiming Wang, Ziping Wang, Dongqing Lv, Rui Ma, Bo Zhu, Ngoc van Tran, Liyan Jiang, Kejun Nan, Konstantin Laktionov, Stephen Clarke, Minghao Song, Helen Mann, Yinglei Liu, Xiaojin Shi, Yi-Long Wu","doi":"10.1016/j.jtho.2024.10.024","DOIUrl":"https://doi.org/10.1016/j.jtho.2024.10.024","url":null,"abstract":"<p><strong>Introduction: </strong>PEARL (NCT03003962) is an open-label, phase 3 study comparing first-line durvalumab monotherapy with chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC [EGFR/ALK wild type]) with PD-L1 tumor cell (TC) membrane expression status ≥25%. We report the final analysis of PEARL.</p><p><strong>Methods: </strong>Adults (N=669) with previously untreated Stage IV mNSCLC were randomized (1:1) to durvalumab 20mg/kg every 4 weeks or chemotherapy every 3 weeks for 4 to 6 cycles. Dual primary endpoints were overall survival (OS) in the PD-L1 TC ≥25% and the PD-L1 TC ≥25% low risk of early mortality (LREM) populations.</p><p><strong>Results: </strong>Durvalumab was associated with a numerical reduction in the risk of death versus chemotherapy in the PD-L1 TC ≥25% population (OS hazard ratio [HR] 0.84, 95% confidence interval [CI] 0.71, 0.99, p = 0.037; median OS 14.6 months [95% CI: 12.2, 16.9] versus 12.8 months [95% CI: 10.1, 14.7], respectively). In the PD-L1 TC ≥25% LREM population the OS HR for durvalumab versus chemotherapy was 0.96 (95% CI: 0.79, 1.15, p = 0.628); median OS 14.6 months (95% CI: 12.6, 17.2) versus 15.0 months (95% CI: 13.1, 16.8), respectively. In the safety population, the incidence of grade 3/4 treatment-related adverse events was 15.5% (durvalumab) and 45.9% (chemotherapy).</p><p><strong>Conclusions: </strong>Durvalumab did not statistically significantly improve OS versus chemotherapy as first-line treatment in patients with mNSCLC and PD-L1 TC ≥25%. The numerical improvement in OS was consistent with previous studies of first-line immune checkpoint inhibitor monotherapy in patients with mNSCLC.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Pembrolizumab联合Olaparib与Pembrolizumab联合培美曲塞作为转移性非鳞状非小细胞肺癌维持疗法的3期KEYLYNK-006研究。
IF 21 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-07 DOI: 10.1016/j.jtho.2024.10.026
Jhanelle E Gray, Michael Schenker, Mehmet Ali Nahit Şendur, Viktoriya Leonova, Dariusz Kowalski, Terufumi Kato, Rashida Orlova, James Chih-Hsin Yang, Adrian Langleben, Arnold Pilz, Andrei Ungureanu, Milena Perez Mak, Flavia De Angelis, Himani Aggarwal, Zachary Zimmer, Bin Zhao, Mark Shamoun, Tae Min Kim

Background: Poly (ADP-ribose) inhibitors, including olaparib, upregulate programmed cell death ligand 1 (PD-L1), which may increase efficacy of anti-PD-(L)1 therapies.

Methods: In the phase 3 KEYLYNK-006 trial (NCT03976323), eligible adults with previously untreated metastatic nonsquamous NSCLC without targetable genetic alterations who had complete response (CR), partial response (PR), or stable disease (SD) following induction therapy with 4 cycles of pembrolizumab 200 mg Q3W, pemetrexed 500 mg/m2 , and carboplatin AUC5 or cisplatin 75 mg/m2 were randomized 1:1 to olaparib 300 mg orally twice daily or pemetrexed Q3W, both given with ≤31 cycles of pembrolizumab Q3W. Dual primary endpoints were progression-free survival (PFS) and overall survival (OS). PFS was tested at interim analysis 2 (IA2; ie, final PFS analysis), OS at final analysis (FA).

Results: Of 1003 patients who received induction therapy, 672 (67.0%) were randomized to pembrolizumab plus olaparib (n=337) or pembrolizumab plus pemetrexed (n=335) in the intention-to-treat population. Median follow-up at FA was 39.9 (range, 28.1-51.5) months. At IA2, median (95% CI) PFS was 7.1 (5.6-8.7) months versus 8.3 (6.9-11.5) months in the olaparib versus pemetrexed groups (HR, 1.12; 95% CI, 0.92-1.36; P=0.87). At FA, median (95% CI) OS was 20.7 (18.0-24.8) months versus 23.0 (19.0-26.4) months (HR, 1.04; 95% CI, 0.87-1.25; P=0.6649). Grade 3-5 maintenance treatment-related AEs occurred in 26.1% versus 30.1% patients.

Conclusion: Pembrolizumab plus maintenance olaparib did not improve PFS or OS versus pembrolizumab plus pemetrexed in previously untreated metastatic nonsquamous NSCLC without targetable genetic alterations.

背景:包括奥拉帕利在内的聚(ADP-核糖)抑制剂会上调程序性细胞死亡配体1(PD-L1),这可能会提高抗PD-(L)1疗法的疗效:在 KEYLYNK-006 3 期试验(NCT03976323)中,符合条件的既往未接受过治疗的转移性非鳞状 NSCLC 患者,如果没有可靶向的基因改变,且在接受 4 个周期的诱导治疗后出现完全应答 (CR)、部分应答 (PR) 或疾病稳定 (SD),则随机分为 1:奥拉帕利(olaparib)300 毫克,口服,每天两次,或培美曲塞 Q3W,均与≤31 个周期的 pembrolizumab Q3W 同时进行。双重主要终点是无进展生存期(PFS)和总生存期(OS)。无进展生存期在中期分析2(IA2;即最终无进展生存期分析)时进行检测,OS在最终分析(FA)时进行检测:在1003名接受诱导治疗的患者中,672人(67.0%)随机接受了pembrolizumab联合奥拉帕利(337人)或pembrolizumab联合培美曲塞(335人)的意向治疗。FA的中位随访时间为39.9个月(28.1-51.5个月)。在IA2,奥拉帕利与培美曲塞组的中位(95% CI)PFS分别为7.1(5.6-8.7)个月和8.3(6.9-11.5)个月(HR,1.12;95% CI,0.92-1.36;P=0.87)。在FA,中位(95% CI)OS为20.7(18.0-24.8)个月对23.0(19.0-26.4)个月(HR,1.04;95% CI,0.87-1.25;P=0.6649)。3-5级维持治疗相关AE发生率为26.1%对30.1%:Pembrolizumab联合奥拉帕利维持治疗与Pembrolizumab联合培美曲塞相比,并不能改善既往未经治疗的无靶向基因改变的转移性非鳞状NSCLC患者的PFS或OS。
{"title":"The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer.","authors":"Jhanelle E Gray, Michael Schenker, Mehmet Ali Nahit Şendur, Viktoriya Leonova, Dariusz Kowalski, Terufumi Kato, Rashida Orlova, James Chih-Hsin Yang, Adrian Langleben, Arnold Pilz, Andrei Ungureanu, Milena Perez Mak, Flavia De Angelis, Himani Aggarwal, Zachary Zimmer, Bin Zhao, Mark Shamoun, Tae Min Kim","doi":"10.1016/j.jtho.2024.10.026","DOIUrl":"https://doi.org/10.1016/j.jtho.2024.10.026","url":null,"abstract":"<p><strong>Background: </strong>Poly (ADP-ribose) inhibitors, including olaparib, upregulate programmed cell death ligand 1 (PD-L1), which may increase efficacy of anti-PD-(L)1 therapies.</p><p><strong>Methods: </strong>In the phase 3 KEYLYNK-006 trial (NCT03976323), eligible adults with previously untreated metastatic nonsquamous NSCLC without targetable genetic alterations who had complete response (CR), partial response (PR), or stable disease (SD) following induction therapy with 4 cycles of pembrolizumab 200 mg Q3W, pemetrexed 500 mg/m<sup>2</sup> , and carboplatin AUC5 or cisplatin 75 mg/m<sup>2</sup> were randomized 1:1 to olaparib 300 mg orally twice daily or pemetrexed Q3W, both given with ≤31 cycles of pembrolizumab Q3W. Dual primary endpoints were progression-free survival (PFS) and overall survival (OS). PFS was tested at interim analysis 2 (IA2; ie, final PFS analysis), OS at final analysis (FA).</p><p><strong>Results: </strong>Of 1003 patients who received induction therapy, 672 (67.0%) were randomized to pembrolizumab plus olaparib (n=337) or pembrolizumab plus pemetrexed (n=335) in the intention-to-treat population. Median follow-up at FA was 39.9 (range, 28.1-51.5) months. At IA2, median (95% CI) PFS was 7.1 (5.6-8.7) months versus 8.3 (6.9-11.5) months in the olaparib versus pemetrexed groups (HR, 1.12; 95% CI, 0.92-1.36; P=0.87). At FA, median (95% CI) OS was 20.7 (18.0-24.8) months versus 23.0 (19.0-26.4) months (HR, 1.04; 95% CI, 0.87-1.25; P=0.6649). Grade 3-5 maintenance treatment-related AEs occurred in 26.1% versus 30.1% patients.</p><p><strong>Conclusion: </strong>Pembrolizumab plus maintenance olaparib did not improve PFS or OS versus pembrolizumab plus pemetrexed in previously untreated metastatic nonsquamous NSCLC without targetable genetic alterations.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiomics-Based Support Vector Machine Distinguishes Molecular Events Driving the Progression of Lung Adenocarcinoma. 基于放射组学的支持向量机区分肺腺癌进展的分子事件
IF 21 1区 医学 Q1 ONCOLOGY Pub Date : 2024-09-19 DOI: 10.1016/j.jtho.2024.09.1431
Hong-Ji Li, Zhen-Bin Qiu, Meng-Min Wang, Chao Zhang, Hui-Zhao Hong, Rui Fu, Li-Shan Peng, Chen Huang, Qian Cui, Jia-Tao Zhang, Jing-Yun Ren, Lei Jiang, Yi-Long Wu, Wen-Zhao Zhong

Introduction: An increasing number of early-stage lung adenocarcinomas (LUAD) are detected as lung nodules. The radiological features related to LUAD progression warrant further investigation. Exploration is required to bridge the gap between radiomics-based features and molecular characteristics of lung nodules.

Methods: Consensus clustering was applied to the radiomic features of 1212 patients to establish stable clustering. Clusters were illustrated using clinicopathological and next-generation sequencing. A classifier was constructed to further investigate the molecular characteristics in patients with paired computed tomography and RNA sequencing data.

Results: Patients were clustered into four clusters. Cluster 1 was associated with a low consolidation-to-tumor ratio, preinvasion, grade I disease, and good prognosis. Clusters 2 and 3 reported increasing malignancy with a higher consolidation-to-tumor ratio, higher pathologic grade, and poor prognosis. Cluster 2 possessed more spread through air spaces and cluster 3 reported a higher proportion of pleural invasion. Cluster 4 had similar clinicopathological features as cluster 1 except but a proportion of grade II disease. RNA sequencing indicated that cluster 1 represented nodules with indolent growth and good differentiation, whereas cluster 4 reported progression in cell development but still had low proliferative activity. Nodules with high proliferation were classified into clusters 2 and 3. In addition, the radiomics classifier distinguished cluster 2 as nodules harboring an activated immune environment, whereas cluster 3 represented nodules with a suppressive immune environment. Furthermore, signatures associated with the prognosis of early-stage LUAD were validated in external datasets.

Conclusions: Radiomics features can manifest molecular events driving the progression of LUAD. Our study provides molecular insight into radiomics features and assists in the diagnosis and treatment of early-stage LUAD.

导言越来越多的早期肺腺癌(LUAD)以肺结节的形式被发现。与 LUAD 进展相关的放射学特征仍有待进一步研究。需要在肺结节的放射学特征和分子特征之间架起一座桥梁:方法:对 1,212 例患者的放射组学特征进行共识聚类,以建立稳定的聚类。利用临床病理学和下一代测序(NGS)对聚类进行了说明。构建了一个分类器,利用成对的CT和RNA-seq数据进一步研究患者的分子特征:结果:患者被分为 4 个群组。结果:患者被分为 4 个群组,群组 1 与低合并瘤比 (CTR)、前浸润、I 级疾病和良好预后相关。第 2 组和第 3 组的恶性程度越来越高,CTR 越高,病理分级越高,预后越差。第 2 组有更多的气隙扩散(STAS),第 3 组的胸膜侵犯比例较高。第 4 组的临床病理特征与第 1 组相似,但 II 级病变的比例较高。RNA-seq表明,第1组代表了生长缓慢、分化良好的结节,而第4组则显示了细胞发育的进展,但增殖活性仍然较低。高增殖的结节被归入第 2 组和第 3 组。此外,放射组学分类器还将第 2 组区分为具有活化免疫环境的结节,而第 3 组则代表具有抑制性免疫环境的结节。此外,与早期LUAD预后相关的基因特征也在外部数据集中得到了验证:结论:放射组学特征可显示肺腺癌进展的分子事件。我们的研究从分子角度揭示了放射组学特征,有助于早期肺腺癌的诊断和治疗。
{"title":"Radiomics-Based Support Vector Machine Distinguishes Molecular Events Driving the Progression of Lung Adenocarcinoma.","authors":"Hong-Ji Li, Zhen-Bin Qiu, Meng-Min Wang, Chao Zhang, Hui-Zhao Hong, Rui Fu, Li-Shan Peng, Chen Huang, Qian Cui, Jia-Tao Zhang, Jing-Yun Ren, Lei Jiang, Yi-Long Wu, Wen-Zhao Zhong","doi":"10.1016/j.jtho.2024.09.1431","DOIUrl":"10.1016/j.jtho.2024.09.1431","url":null,"abstract":"<p><strong>Introduction: </strong>An increasing number of early-stage lung adenocarcinomas (LUAD) are detected as lung nodules. The radiological features related to LUAD progression warrant further investigation. Exploration is required to bridge the gap between radiomics-based features and molecular characteristics of lung nodules.</p><p><strong>Methods: </strong>Consensus clustering was applied to the radiomic features of 1212 patients to establish stable clustering. Clusters were illustrated using clinicopathological and next-generation sequencing. A classifier was constructed to further investigate the molecular characteristics in patients with paired computed tomography and RNA sequencing data.</p><p><strong>Results: </strong>Patients were clustered into four clusters. Cluster 1 was associated with a low consolidation-to-tumor ratio, preinvasion, grade I disease, and good prognosis. Clusters 2 and 3 reported increasing malignancy with a higher consolidation-to-tumor ratio, higher pathologic grade, and poor prognosis. Cluster 2 possessed more spread through air spaces and cluster 3 reported a higher proportion of pleural invasion. Cluster 4 had similar clinicopathological features as cluster 1 except but a proportion of grade II disease. RNA sequencing indicated that cluster 1 represented nodules with indolent growth and good differentiation, whereas cluster 4 reported progression in cell development but still had low proliferative activity. Nodules with high proliferation were classified into clusters 2 and 3. In addition, the radiomics classifier distinguished cluster 2 as nodules harboring an activated immune environment, whereas cluster 3 represented nodules with a suppressive immune environment. Furthermore, signatures associated with the prognosis of early-stage LUAD were validated in external datasets.</p><p><strong>Conclusions: </strong>Radiomics features can manifest molecular events driving the progression of LUAD. Our study provides molecular insight into radiomics features and assists in the diagnosis and treatment of early-stage LUAD.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142290063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer IASLC癌症分期项目:对即将出版的第9版癌症TNM分类中N描述符的修订建议。
IF 20.4 1区 医学 Q1 ONCOLOGY Pub Date : 2024-05-01 DOI: 10.1016/j.jtho.2023.10.012
James Huang MD , Raymond U. Osarogiagbon M.B.B.S., FACP , Dorothy J. Giroux MS , Katherine K. Nishimura PhD, MPH , Andrea Bille MD, PhD , Giuseppe Cardillo FRCS, FETCS , Frank Detterbeck MD , Kemp Kernstine MD, PhD , Hong Kwan Kim MD, PhD , Yolande Lievens MD, PhD , Eric Lim MB, ChB, MD, MSc, FRCS(C-Th) , Edith Marom MD , Helmut Prosch MD , Paul Martin Putora MD, PhD, MA, MHI , Ramon Rami-Porta MD , David Rice MB, BCh , Gaetano Rocco MD, FACS, FRCSEd, FEBTS , Valerie W. Rusch MD , Isabelle Opitz MD , Francisco Suarez Vasquez MD , Hisao Asamura MD

Introduction

The accurate assessment of nodal (N) status is crucial to the management and prognostication of nonmetastatic NSCLC. We sought to determine whether the current N descriptors should be maintained or revised for the upcoming ninth edition of the international TNM lung cancer staging system.

Methods

Data were assembled by the International Association for the Study of Lung Cancer on patients with NSCLC, detailing both clinical and pathologic N status, with information about anatomical location and individual station-level identification. Survival was calculated by the Kaplan-Meier method and prognostic groups were assessed by a Cox regression analysis.

Results

Data for clinical N and pathologic N status were available in 45,032 and 35,009 patients, respectively. The current N0 to N3 descriptors for both clinical N and pathologic N categories reflect prognostically distinct groups. Furthermore, single-station N2 involvement (N2a) exhibited a better prognosis than multistation N2 involvement (N2b) in both clinical and pathologic classifications, and the differences between all neighboring nodal subcategories were highly significant. The prognostic differences between N2a and N2b were robust and consistent across resection status, histologic type, T category, and geographic region.

Conclusions

The current N descriptors should be maintained, with the addition of new subdescriptors to N2 for single-station involvement (N2a) and multiple-station involvement (N2b).

引言:准确评估结(N)状态对于非侵袭性非小细胞肺癌癌症的治疗和预后至关重要。我们试图确定当前的N描述符是否应该为即将发布的第9版国际肿瘤节点转移(TNM)癌症分期系统保留或修改。方法:由国际癌症研究协会收集的非小细胞肺癌癌症患者的数据,详细说明临床和病理N状态,包括解剖位置和个体站级识别信息。通过Kaplan-Meier方法计算生存率,并通过Cox回归分析评估预后组。结果:分别有45032例和35009例患者的临床N和病理N状态数据。目前临床N和病理N类别的N0至N3描述符显示了预后不同的组。此外,在临床和病理分类中,单站N2受累(N2a)表现出比多站N2累及(N2b)更好的预后,并且所有相邻淋巴结亚类之间的差异非常显著。N2a和N2b之间的预后差异在切除状态、组织学类型、T类和地理区域方面是稳健和一致的。结论:应保留当前的N个描述符,在N2中添加新的子描述符,用于单站参与(N2a)和多站参与(N2 b)。
{"title":"The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer","authors":"James Huang MD ,&nbsp;Raymond U. Osarogiagbon M.B.B.S., FACP ,&nbsp;Dorothy J. Giroux MS ,&nbsp;Katherine K. Nishimura PhD, MPH ,&nbsp;Andrea Bille MD, PhD ,&nbsp;Giuseppe Cardillo FRCS, FETCS ,&nbsp;Frank Detterbeck MD ,&nbsp;Kemp Kernstine MD, PhD ,&nbsp;Hong Kwan Kim MD, PhD ,&nbsp;Yolande Lievens MD, PhD ,&nbsp;Eric Lim MB, ChB, MD, MSc, FRCS(C-Th) ,&nbsp;Edith Marom MD ,&nbsp;Helmut Prosch MD ,&nbsp;Paul Martin Putora MD, PhD, MA, MHI ,&nbsp;Ramon Rami-Porta MD ,&nbsp;David Rice MB, BCh ,&nbsp;Gaetano Rocco MD, FACS, FRCSEd, FEBTS ,&nbsp;Valerie W. Rusch MD ,&nbsp;Isabelle Opitz MD ,&nbsp;Francisco Suarez Vasquez MD ,&nbsp;Hisao Asamura MD","doi":"10.1016/j.jtho.2023.10.012","DOIUrl":"10.1016/j.jtho.2023.10.012","url":null,"abstract":"<div><h3>Introduction</h3><p>The accurate assessment of nodal (N) status is crucial to the management and prognostication of nonmetastatic NSCLC. We sought to determine whether the current N descriptors should be maintained or revised for the upcoming ninth edition of the international TNM lung cancer staging system.</p></div><div><h3>Methods</h3><p>Data were assembled by the International Association for the Study of Lung Cancer on patients with NSCLC, detailing both clinical and pathologic N status, with information about anatomical location and individual station-level identification. Survival was calculated by the Kaplan-Meier method and prognostic groups were assessed by a Cox regression analysis.</p></div><div><h3>Results</h3><p>Data for clinical N and pathologic N status were available in 45,032 and 35,009 patients, respectively. The current N0 to N3 descriptors for both clinical N and pathologic N categories reflect prognostically distinct groups. Furthermore, single-station N2 involvement (N2a) exhibited a better prognosis than multistation N2 involvement (N2b) in both clinical and pathologic classifications, and the differences between all neighboring nodal subcategories were highly significant. The prognostic differences between N2a and N2b were robust and consistent across resection status, histologic type, T category, and geographic region.</p></div><div><h3>Conclusions</h3><p>The current N descriptors should be maintained, with the addition of new subdescriptors to N2 for single-station involvement (N2a) and multiple-station involvement (N2b).</p></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 5","pages":"Pages 766-785"},"PeriodicalIF":20.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1556086423023109/pdfft?md5=00a02583623d5c7262d416c2781bd6d6&pid=1-s2.0-S1556086423023109-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49691184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation 微卫星不稳定性和错配修复缺陷定义了一个独特的肺癌亚群,其特征是吸烟暴露、高肿瘤突变负担和复发性体细胞MLH1失活。
IF 20.4 1区 医学 Q1 ONCOLOGY Pub Date : 2024-03-01 DOI: 10.1016/j.jtho.2023.10.004
Soo-Ryum Yang MD , Erika Gedvilaite MA , Ryan Ptashkin MS , Jason Chang MD , John Ziegler MS , Douglas A. Mata MD, MPH , Liliana B. Villafania BS , Khedoudja Nafa PharmD, PhD , Jaclyn F. Hechtman MD , Ryma Benayed PhD , Ahmet Zehir PhD , Jamal Benhamida MD , Maria E. Arcila MD , Diana Mandelker MD, PhD , Charles M. Rudin MD, PhD , Paul K. Paik MD , Alexander Drilon MD , Adam J. Schoenfeld MD , Marc Ladanyi MD

Introduction

Microsatellite instability (MSI) and mismatch repair (MMR) deficiency represent a distinct oncogenic process and predict response to immune checkpoint inhibitors (ICIs). The clinicopathologic features of MSI-high (MSI-H) and MMR deficiency (MMR-D) in lung cancers remain poorly characterized.

Methods

MSI status from 5171 patients with NSCLC and 315 patients with SCLC was analyzed from targeted next-generation sequencing data using two validated bioinformatic pipelines.

Results

MSI-H and MMR-D were identified in 21 patients with NSCLC (0.41%) and six patients with SCLC (1.9%). Notably, all patients with NSCLC had a positive smoking history, including 11 adenocarcinomas. Compared with microsatellite stable cases, MSI-H was associated with exceptionally high tumor mutational burden (37.4 versus 8.5 muts/Mb, p < 0.0001), MMR mutational signatures (43% versus 0%, p < 0.0001), and somatic biallelic alterations in MLH1 (52% versus 0%, p < 0.0001). Loss of MLH1 and PMS2 expression by immunohistochemistry was found in MLH1 altered and wild-type cases. Similarly, the majority of patients with MSI-H SCLC had evidence of MLH1 inactivation, including two with MLH1 promoter hypermethylation. A single patient with NSCLC with a somatic MSH2 mutation had Lynch syndrome as confirmed by the presence of a germline MSH2 mutation. Among patients with advanced MSI-H lung cancers treated with ICIs, durable clinical benefit was observed in three of eight patients with NSCLC and two of two patients with SCLC. In NSCLC, STK11, KEAP1, and JAK1 were mutated in nonresponders but wild type in responders.

Conclusions

We present a comprehensive clinicogenomic landscape of MSI-H lung cancers and reveal that MSI-H defines a rare subset of lung cancers associated with smoking, high tumor mutational burden, and MLH1 inactivation. Although durable clinical benefit to ICI was observed in some patients, the broad range of responses suggests that clinical activity may be modulated by co-mutational landscapes.

引言:微卫星不稳定性(MSI)和错配修复(MMR)缺陷代表了一个独特的致癌过程,并预测了对免疫检查点抑制剂(ICIs)的反应。肺癌MSI高(MSI-H)和MMR缺乏(MMR-D)的临床病理特征仍不明确。方法:使用两条经验证的生物信息学管道,从靶向下一代测序数据中分析5171例癌症(NSCLC)患者和315例癌症(SCLC)患者的MSI状态。结果:21例(0.41%)NSCLC和6例(1.9%)SCLC患者中发现MSI-H/MMR-D。值得注意的是,所有NSCLC组织学患者都有阳性吸烟史,包括11例腺癌。与微卫星稳定的病例相比,MSI-H/MMR-D与异常高的肿瘤突变负荷(TMB)相关(37.4 vs.8.5muts/Mb,P结论:我们提供了MSI-H/MMR-D肺癌的全面临床基因组景观,并证明MSI-H/MRR-D定义了与吸烟、高TMB和MLH1失活相关的罕见肺癌亚群。虽然在一些患者中观察到DCB对ICI的反应,但广泛的反应表明临床活性可能受到共突变景观的调节s
{"title":"Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation","authors":"Soo-Ryum Yang MD ,&nbsp;Erika Gedvilaite MA ,&nbsp;Ryan Ptashkin MS ,&nbsp;Jason Chang MD ,&nbsp;John Ziegler MS ,&nbsp;Douglas A. Mata MD, MPH ,&nbsp;Liliana B. Villafania BS ,&nbsp;Khedoudja Nafa PharmD, PhD ,&nbsp;Jaclyn F. Hechtman MD ,&nbsp;Ryma Benayed PhD ,&nbsp;Ahmet Zehir PhD ,&nbsp;Jamal Benhamida MD ,&nbsp;Maria E. Arcila MD ,&nbsp;Diana Mandelker MD, PhD ,&nbsp;Charles M. Rudin MD, PhD ,&nbsp;Paul K. Paik MD ,&nbsp;Alexander Drilon MD ,&nbsp;Adam J. Schoenfeld MD ,&nbsp;Marc Ladanyi MD","doi":"10.1016/j.jtho.2023.10.004","DOIUrl":"10.1016/j.jtho.2023.10.004","url":null,"abstract":"<div><h3>Introduction</h3><p><span>Microsatellite instability (MSI) and </span>mismatch repair<span> (MMR) deficiency represent a distinct oncogenic process and predict response to immune checkpoint inhibitors (ICIs). The clinicopathologic features of MSI-high (MSI-H) and MMR deficiency (MMR-D) in lung cancers remain poorly characterized.</span></p></div><div><h3>Methods</h3><p>MSI status from 5171 patients with NSCLC and 315 patients with SCLC was analyzed from targeted next-generation sequencing data using two validated bioinformatic pipelines.</p></div><div><h3>Results</h3><p>MSI-H and MMR-D were identified in 21 patients with NSCLC (0.41%) and six patients with SCLC (1.9%). Notably, all patients with NSCLC had a positive smoking history, including 11 adenocarcinomas. Compared with microsatellite stable cases, MSI-H was associated with exceptionally high tumor mutational burden (37.4 versus 8.5 muts/Mb, <em>p</em> &lt; 0.0001), MMR mutational signatures (43% versus 0%, <em>p</em> &lt; 0.0001), and somatic biallelic alterations in <em>MLH1</em> (52% versus 0%, <em>p</em><span> &lt; 0.0001). Loss of MLH1 and PMS2 expression by immunohistochemistry was found in </span><em>MLH1</em> altered and wild-type cases. Similarly, the majority of patients with MSI-H SCLC had evidence of <em>MLH1</em> inactivation, including two with <em>MLH1</em> promoter hypermethylation. A single patient with NSCLC with a somatic <em>MSH2</em><span> mutation had Lynch syndrome as confirmed by the presence of a germline </span><em>MSH2</em> mutation. Among patients with advanced MSI-H lung cancers treated with ICIs, durable clinical benefit was observed in three of eight patients with NSCLC and two of two patients with SCLC. In NSCLC, <em>STK11</em>, <em>KEAP1</em>, and <em>JAK1</em> were mutated in nonresponders but wild type in responders.</p></div><div><h3>Conclusions</h3><p>We present a comprehensive clinicogenomic landscape of MSI-H lung cancers and reveal that MSI-H defines a rare subset of lung cancers associated with smoking, high tumor mutational burden, and <em>MLH1</em> inactivation. Although durable clinical benefit to ICI was observed in some patients, the broad range of responses suggests that clinical activity may be modulated by co-mutational landscapes.</p></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 3","pages":"Pages 409-424"},"PeriodicalIF":20.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41204197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC MUC1-C是非小细胞肺癌获得性奥西替尼耐药性的常见驱动因素。
IF 20.4 1区 医学 Q1 ONCOLOGY Pub Date : 2024-03-01 DOI: 10.1016/j.jtho.2023.10.017
Naoki Haratake MD, PhD , Hiroki Ozawa MD, PhD , Yoshihiro Morimoto MD, PhD , Nami Yamashita MD, PhD , Tatsuaki Daimon MD, PhD , Atrayee Bhattacharya PhD , Keyi Wang MD , Ayako Nakashoji MD, PhD , Hideko Isozaki PhD , Mototsugu Shimokawa PhD , Chie Kikutake PhD , Mikita Suyama PhD , Asato Hashinokuchi MD , Kazuki Takada MD, PhD , Tomoyoshi Takenaka MD, PhD , Tomoharu Yoshizumi MD, PhD , Tetsuya Mitsudomi MD, PhD , Aaron N. Hata MD, PhD , Donald Kufe MD

Introduction

Osimertinib is an irreversible EGFR tyrosine kinase inhibitor approved for the first-line treatment of patients with metastatic NSCLC harboring EGFR exon 19 deletions or L858R mutations. Patients treated with osimertinib invariably develop acquired resistance by mechanisms involving additional EGFR mutations, MET amplification, and other pathways. There is no known involvement of the oncogenic MUC1-C protein in acquired osimertinib resistance.

Methods

H1975/EGFR (L858R/T790M) and patient-derived NSCLC cells with acquired osimertinib resistance were investigated for MUC1-C dependence in studies of EGFR pathway activation, clonogenicity, and self-renewal capacity.

Results

We reveal that MUC1-C is up-regulated in H1975 osimertinib drug-tolerant persister cells and is necessary for activation of the EGFR pathway. H1975 cells selected for stable osimertinib resistance (H1975-OR) and MGH700-2D cells isolated from a patient with acquired osimertinib resistance are found to be dependent on MUC1-C for induction of (1) phospho (p)-EGFR, p-ERK, and p-AKT, (2) EMT, and (3) the resistant phenotype. We report that MUC1-C is also required for p-EGFR, p-ERK, and p-AKT activation and self-renewal capacity in acquired osimertinib-resistant (1) MET-amplified MGH170-1D #2 cells and (2) MGH121 Res#2/EGFR (T790M/C797S) cells. Importantly, targeting MUC1-C in these diverse models reverses osimertinib resistance. In support of these results, high MUC1 mRNA and MUC1-C protein expression is associated with a poor prognosis for patients with EGFR-mutant NSCLCs.

Conclusions

Our findings reveal that MUC1-C is a common effector of osimertinib resistance and is a potential target for the treatment of osimertinib-resistant NSCLCs.

背景:Osimertinib是一种不可逆的EGFR酪氨酸激酶抑制剂,被批准用于一线治疗携带EGFR外显子19缺失或L858R突变的转移性NSCLC患者。奥西替尼治疗的患者总是通过涉及额外EGFR突变、MET扩增和其他途径的机制产生获得性耐药性。目前还没有已知致癌MUC1-C蛋白参与获得性奥西替尼耐药性。方法:对H1975/EGFR(L858R/T790M)和具有获得性奥西替尼耐药性的患者来源的NSCLC细胞的MUC1-C依赖性进行研究,以研究EGFR通路的激活、克隆发生性和自我更新能力。结果:我们证明MUC1-C在H1975奥西替尼药物耐受性persister(DTP)细胞中上调,并且是激活EGFR途径所必需的。从具有获得性奥西替尼抗性的患者中分离的用于稳定奥西替尼抗性的H1975细胞(H1975-OR)和MGH700-2D细胞显示依赖于MUC1-C来诱导(i)p-EGFR、p-ERK和p-AKT,(ii)EMT,和(iii)抗性表型。我们报道,在获得性奥西替尼抗性(i)MET扩增的MGH170-1D#2细胞和(ii)MGH121-Res#2/EGFR(T790M/C797S)细胞中,MUC1-C也是p-EGFR、p-ERK和p-AKT激活和自我更新能力所必需的。重要的是,在这些不同的模型中靶向MUC1-C可以逆转奥西替尼的耐药性。为了支持这些结果,高MUC1mRNA和MUC1-C蛋白表达与EGFR突变NSCLC患者的不良预后相关。结论:我们的研究结果表明,MUC1-C是奥西替尼耐药性的常见效应物,是治疗奥西替尼非小细胞肺癌的潜在靶点。
{"title":"MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC","authors":"Naoki Haratake MD, PhD ,&nbsp;Hiroki Ozawa MD, PhD ,&nbsp;Yoshihiro Morimoto MD, PhD ,&nbsp;Nami Yamashita MD, PhD ,&nbsp;Tatsuaki Daimon MD, PhD ,&nbsp;Atrayee Bhattacharya PhD ,&nbsp;Keyi Wang MD ,&nbsp;Ayako Nakashoji MD, PhD ,&nbsp;Hideko Isozaki PhD ,&nbsp;Mototsugu Shimokawa PhD ,&nbsp;Chie Kikutake PhD ,&nbsp;Mikita Suyama PhD ,&nbsp;Asato Hashinokuchi MD ,&nbsp;Kazuki Takada MD, PhD ,&nbsp;Tomoyoshi Takenaka MD, PhD ,&nbsp;Tomoharu Yoshizumi MD, PhD ,&nbsp;Tetsuya Mitsudomi MD, PhD ,&nbsp;Aaron N. Hata MD, PhD ,&nbsp;Donald Kufe MD","doi":"10.1016/j.jtho.2023.10.017","DOIUrl":"10.1016/j.jtho.2023.10.017","url":null,"abstract":"<div><h3>Introduction</h3><p>Osimertinib is an irreversible EGFR tyrosine kinase inhibitor approved for the first-line treatment of patients with metastatic NSCLC harboring <em>EGFR</em> exon 19 deletions or L858R mutations. Patients treated with osimertinib invariably develop acquired resistance by mechanisms involving additional <em>EGFR</em> mutations, <em>MET</em> amplification, and other pathways. There is no known involvement of the oncogenic MUC1-C protein in acquired osimertinib resistance.</p></div><div><h3>Methods</h3><p>H1975/EGFR (L858R/T790M) and patient-derived NSCLC cells with acquired osimertinib resistance were investigated for MUC1-C dependence in studies of EGFR pathway activation, clonogenicity, and self-renewal capacity.</p></div><div><h3>Results</h3><p>We reveal that MUC1-C is up-regulated in H1975 osimertinib drug-tolerant persister cells and is necessary for activation of the EGFR pathway. H1975 cells selected for stable osimertinib resistance (H1975-OR) and MGH700-2D cells isolated from a patient with acquired osimertinib resistance are found to be dependent on MUC1-C for induction of (1) phospho (p)-EGFR, p-ERK, and p-AKT, (2) EMT, and (3) the resistant phenotype. We report that MUC1-C is also required for p-EGFR, p-ERK, and p-AKT activation and self-renewal capacity in acquired osimertinib-resistant (1) <em>MET-</em>amplified MGH170-1D #2 cells and (2) MGH121 Res#2/EGFR (T790M/C797S) cells. Importantly, targeting MUC1-C in these diverse models reverses osimertinib resistance. In support of these results, high MUC1 mRNA and MUC1-C protein expression is associated with a poor prognosis for patients with EGFR-mutant NSCLCs.</p></div><div><h3>Conclusions</h3><p>Our findings reveal that MUC1-C is a common effector of osimertinib resistance and is a potential target for the treatment of osimertinib-resistant NSCLCs.</p></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 3","pages":"Pages 434-450"},"PeriodicalIF":20.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1556086423023481/pdfft?md5=489687c09cb071e4f202ac91b19cce29&pid=1-s2.0-S1556086423023481-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71483033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Thoracic Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1